The clinical effect of azithromycin and erythromycin in the treatment of mycoplasma pneumoniae pneumonia in children
Objective To investigate the clinical effect of azithromycin and erythromycin in the treatment of mycoplasma pneumoniae pneumonia in children.Methods 50 children with mycoplasma pneumoniae pneumonia were selected and divided into a control group and an observation group by random number table method,with 25 cases in each group.The control group was treated with erythromycin,and the observation group was treated with azithromycin.The therapeutic effect,cough score,cough disappearance time,inflammatory factor level,lung function,clinical symptom improvement time and length of hospital stay were compared between the two groups.Results Before treatment,there was no significant difference in cough score between the two groups(P>0.05).After treatment,the cough score in both groups decreased compared with that before treatment;the observation group had lower cough score of(0.61±0.03)points than(1.03±0.07)points in the control group(P<0.05);the observation group had shorter cough disappearance time of(6.84±1.29)d than(10.54±2.01)d in the control group,and the difference was statistically significant(P<0.05).The total clinical effective rate of the observation group was 96.00%,which was significantly higher than 72.00%of the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)and interleukin-10(IL-10)levels between the two groups(P>0.05).After treatment,CRP and TNF-α decreased and IL-10 increased in both groups compared with those before treatment;the observation group had CRP of(7.19±1.13)mg/L and TNF-α of(5.97±2.08)µg/L,which were lower than(10.40±1.42)mg/L and(9.63±3.72)µg/L in the control group;the observation group had higher IL-10 of(158.47±15.33)ng/L than(127.80±12.39)ng/L in the control group;the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the maximum expiratory time,maximum voluntary ventilation(MVV)and forced expiratory volume in one second(FEV1)as a percentage of the predicted value between the two groups(P>0.05).After treatment,the maximum expiratory time,MVV,FEV1 as a percentage of the predicted value in both groups were higher than those before treatment;the observation group had longer maximum expiratory time of(8.48±0.88)d than(4.50±0.46)d in the control group;the observation group had MVV of(81.65±7.16)L and FEV1 as a percentage of the predicted value of(83.20±5.26)%,which were higher than(71.97±6.40)L and(74.93±3.95)%in the control group;the difference was statistically significant(P<0.05).In the control group,the time of fever reduction was(7.52±2.06)d,the disappearance time of lung shadow was(10.22±2.43)d and the length of hospital stay was(11.24±2.11)d,and those in the observation group were(3.83±1.03),(7.41±1.29)and(9.35±2.11)d;the observation group was significant shorter,and the difference was statistically significant(P<0.05).Conclusion The clinical effect of azithromycin in the treatment of mycoplasma pneumoniae pneumonia in children is better than erythromycin,which is conducive to improving the cough symptoms of children,and can effectively improve the level of inflammatory factors and lung function in children,which is worthy of promotion and application.
AzithromycinErythromycinMycoplasma pneumoniae pneumoniaInflammatory factorsLung function
NETL
NSTL
万方数据
维普
